Igor Espinoza‐Delgado

Author

Also Known As

I Espinoza-Delgado, I EspinozaDelgado, I. Espinoza-Delgado, I. J. Espinoza-Delgado, Igor Espinoza-Delgado, Igor Espinoza‐Delgado, Igor J. Espinoza-Delgado, Weitzman, Aaron

112

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Frederick National Laboratory for Cancer Research Istituto Giannina Gaslini UPMC Hillman Cancer Center

About

Igor Espinoza‐Delgado is an author at National Cancer Institute specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	27	1.5K
2	Cell Biology	10	10	401
3	Health Sciences	4	4	82
4	Allergy	1	1	108
5	Blood Transplantation	1	1	115

Igor Espinoza‐Delgado

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Tamer E. Fandy, James G. Herman, Patrick Kerns, Blood	2009	286
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Journal of Clinical Oncology Purpose VorinostatAdvanced NsclcFirst-line TherapyOncologyMetronomic Therapy	2009	267
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma Ashraf Badros, Angelika M. Burger, Sunita Philip, Clinical Cancer Research	2009	229
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Mark Kirschbaum, Paul Frankel, Leslie Popplewell, Journal of Clinical Oncology	2011	211
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors Giuseppe Giaccone, Arun Rajan, Arlene Berman, Journal of Clinical Oncology	2011	186
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Journal of Thoracic Oncology OncologyHistone Deacetylase InhibitorMedicinePhase Ii StudyPathology	2009	157
Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study Anne M. Traynor, Sarita Dubey, Jens C. Eickhoff, Journal of Thoracic Oncology Tumor BiologyMedicineCancer ManagementPathologyBronchial Neoplasm	2009	139
A phase 2 study of vorinostat in acute myeloid leukemia Élise Schaefer, Arturo Loaiza‐Bonilla, Mark Juckett, Haematologica	2009	117
Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation Ramaprasad Srinivasan, Yoshiyuki Takahashi, J. Philip McCoy, British Journal of Haematology ImmunologyPnh PatientsImmunotherapyAplastic AnemiaChronic Gvhd	2006	115
Expression and role of p75 interleukin 2 receptor on human monocytes. Igor Espinoza‐Delgado, John R. Ortaldo, Robin Winkler-Pickett, The Journal of Experimental Medicine ImmunologyImmune RegulationCell DeathImmunologic MechanismTu27 Mab	1990	108

Page 1